PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 37 filers reported holding PROQR THRAPEUTICS N V in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $28,075,000 | +458.6% | 1,450,925 | -6.9% | 0.86% | +294.5% |
Q4 2017 | $5,026,000 | -35.3% | 1,558,392 | -2.8% | 0.22% | -42.8% |
Q3 2017 | $7,774,000 | -6.3% | 1,602,975 | +0.4% | 0.38% | -24.2% |
Q2 2017 | $8,301,000 | +6.9% | 1,596,275 | +2.8% | 0.50% | +0.2% |
Q1 2017 | $7,766,000 | +0.4% | 1,553,225 | -1.6% | 0.50% | -24.4% |
Q4 2016 | $7,733,000 | +101.3% | 1,578,174 | +174.1% | 0.67% | +118.7% |
Q3 2016 | $3,841,000 | +36.4% | 575,863 | -1.0% | 0.30% | +13.4% |
Q2 2016 | $2,815,000 | +4.4% | 581,638 | +5.2% | 0.27% | -2.5% |
Q1 2016 | $2,697,000 | -44.2% | 552,713 | -0.8% | 0.28% | -23.8% |
Q4 2015 | $4,836,000 | -49.8% | 557,193 | -15.7% | 0.36% | -50.3% |
Q3 2015 | $9,628,000 | +11.8% | 660,816 | +27.9% | 0.73% | +3.3% |
Q2 2015 | $8,613,000 | -47.6% | 516,690 | -31.2% | 0.71% | -52.2% |
Q1 2015 | $16,436,000 | +4.5% | 751,171 | 0.0% | 1.48% | -13.8% |
Q4 2014 | $15,729,000 | +30.3% | 751,171 | -1.8% | 1.71% | +22.9% |
Q3 2014 | $12,067,000 | – | 765,232 | – | 1.39% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 748,861 | $6,815,000 | 2.37% |
Opus Point Partners Management, LLC | 138,461 | $1,260,000 | 1.86% |
RTW INVESTMENTS, LP | 3,722,950 | $33,879,000 | 1.81% |
Kerrisdale Advisers, LLC | 465,580 | $4,237,000 | 1.52% |
DAFNA Capital Management LLC | 261,521 | $2,380,000 | 0.90% |
SPHERA FUNDS MANAGEMENT LTD. | 470,000 | $4,277,000 | 0.58% |
Artal Group S.A. | 1,300,000 | $11,830,000 | 0.48% |
Orbimed Advisors | 1,382,502 | $12,581,000 | 0.20% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 56,000 | $511,000 | 0.19% |
ALTRINSIC GLOBAL ADVISORS LLC | 201,360 | $1,832,000 | 0.08% |